INCPF (InnoCare Pharma) Other Long-Term Liabilities: $54.2 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INCPF InnoCare Pharma Ltd INCPF
83 GF Score
Price $1.55
GF Value $2.32
! 7 Warning Signs
View Full Analysis

What is InnoCare Pharma Other Long-Term Liabilities?

InnoCare Pharma INCPF 83 Other Long-Term Liabilities is $54.2 Mil as of Dec. 2025. GuruFocus rates INCPF with a GF Score™ of 83/100 and a GF Value™ of $2.32. The stock has 7 warning signs investors should review.

InnoCare Pharma's other long-term liabilities for the quarter that ended in Dec. 2025 was $54.2 Mil.

InnoCare Pharma's quarterly other long-term liabilities declined from Dec. 2024 ($34.5 Mil) to Jun. 2025 ($34.2 Mil) but then increased from Jun. 2025 ($34.2 Mil) to Dec. 2025 ($54.2 Mil).

InnoCare Pharma's annual other long-term liabilities declined from Dec. 2023 ($37.7 Mil) to Dec. 2024 ($34.5 Mil) but then increased from Dec. 2024 ($34.5 Mil) to Dec. 2025 ($54.2 Mil).

InnoCare Pharma Other Long-Term Liabilities Related Terms

InnoCare Pharma Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for InnoCare Pharma's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InnoCare Pharma Other Long-Term Liabilities Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only 19.41 39.91 37.66 34.51 54.22

InnoCare Pharma Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 37.66 35.61 34.51 34.21 54.22
INCPF
83GF Score
InnoCare Pharma Ltd INCPF
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InnoCare Pharma Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $54.2 Mil mean?
InnoCare Pharma (INCPF) has a Other Long-Term Liabilities of $54.2 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on InnoCare Pharma and its competitors.
Is InnoCare Pharma's Other Long-Term Liabilities too high?
InnoCare Pharma's current Other Long-Term Liabilities is $54.2 Mil. Overall, InnoCare Pharma has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's Other Long-Term Liabilities compare to VRTX and REGN?
InnoCare Pharma's Other Long-Term Liabilities of $54.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on InnoCare Pharma and its competitors. InnoCare Pharma's current Other Long-Term Liabilities is $54.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
InnoCare Pharma (INCPF) has a current Other Long-Term Liabilities of $54.2 Mil. The stock's GF Value™ is $2.32, compared to a current price of $1.55 — trading 33.2% below its estimated fair value. The current Other Long-Term Liabilities is $54.2 Mil. InnoCare Pharma's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For InnoCare Pharma (INCPF), the current Other Long-Term Liabilities is $54.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is InnoCare Pharma (INCPF) Overvalued in 2026?

Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued. The current stock price of $1.55 is trading 33.2% below its estimated GF Value™ of $2.32.

Key valuation signals for INCPF:

  • Other Long-Term Liabilities: $54.2 Mil
  • GF Value™: $2.32 vs. price of $1.55 (33.2% below fair value)
  • GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the INCPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

InnoCare Pharma Business Description

Address No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
83GF Score

Get the complete analysis for INCPF

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.55
Price
$2.32
GF Value